Research graph
References from Assessment of the Fasciola hepatica saposin-like protein 2 (rFhSAP2) vaccine candidate in sheep: Immunogenicity without protective efficacy. Local targets link to admitted publications; unresolved targets remain external evidence.
Epidemiology of fascioliasis in human endemic areas
10.1079/joh2005296 · 2005 · External reference
Chapter 2 Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control
10.1016/s0065-308x(09)69002-3 · 2009 · External reference
An update on the pathogenesis of fascioliasis: what do we know?
2024 · External reference
<i>Fasciola hepatica</i> vaccine: we may not be there yet but we’re on the right road
10.1016/j.vetpar.2015.01.004 · 2015 · External reference
Fasciolosis—an increasing challenge in the sheep industry
10.3390/ani12121491 · 2022 · External reference
Human and animal fascioliasis: origins and worldwide evolving scenario
10.1128/cmr.00088-19 · 2022 · External reference
Triclabendazole and other fasciolicides: resistance of Fasciola hepatica in ruminants
10.3390/ani16071044 · 2026 · External reference
Dynamic immune modulation in fasciolosis: from protective to permissive responses
10.1016/j.actatropica.2026.108087 · 2026 · External reference
Omics tools enabling vaccine discovery against fasciolosis
10.1016/j.pt.2022.09.009 · 2022 · External reference
Moderate protection is induced by a chimeric protein composed of leucine aminopeptidase and cathepsin L1 against Fasciola hepatica challenge in sheep
10.1016/j.vaccine.2019.04.067 · 2019 · External reference
Evaluation of Quillaja brasiliensis saponin-based nanoparticles combined with leucine aminopeptidases for immunoprotection of sheep against Fasciola hepatica
10.3390/vaccines13101008 · 2025 · External reference
Fasciola hepatica antioxidant and protease-inhibitor cocktail recombinant vaccines administered five times elicit potent and sustained immune responses in sheep but do not confer protection
10.1016/j.vetpar.2023.110049 · 2023 · External reference
Fasciola hepatica: vaccination of rabbits with native and recombinant antigens related to fatty acid binding proteins
10.1016/s0304-4017(96)01131-4 · 1997 · External reference
Fasciola hepatica vaccine based on Kunitz-type molecule reduces adult worm fecundity in experimentally infected sheep
10.1016/j.vetpar.2025.110654 · 2026 · External reference
Quantitation of cytokine mRNA by real-time RT-PCR during a vaccination trial in a rabbit model of fascioliasis
10.1016/j.vetpar.2009.12.018 · 2009 · External reference
Differential expression and localization of saposin-like protein 2 of Fasciola hepatica
10.1016/j.actatropica.2013.08.012 · 2013 · External reference
Molecular cloning of a member of the Fasciola hepatica saposin-like protein family
10.1645/ge-3113 · 2003 · External reference
Fasciola hepatica saposin-like protein-2-based ELISA for the serodiagnosis of chronic human fascioliasis
10.1016/j.diagmicrobio.2011.03.016 · 2011 · External reference
Expression, purification and in vitro refolding of the recombinant truncated Saposin-like protein 2 antigen for development of diagnosis of human fascioliasis
10.1016/j.actatropica.2017.03.002 · 2017 · External reference
Adjuvant-enhanced antibody and cellular responses to inclusion bodies expressing FhSAP2 correlates with protection of mice to Fasciola hepatica
10.1016/j.exppara.2015.11.002 · 2016 · External reference
Fasciola hepatica: humoral and cytokine responses to a member of the saposin-like protein family following delivery as a DNA vaccine in mice
10.1016/j.exppara.2005.03.029 · 2005 · External reference
Fasciola hepatica: identification of CD4+ T-helper epitopes from the 11.5kDa Saposin-like protein SAP-2 using synthetic peptides
10.1016/j.exppara.2007.03.012 · 2007 · External reference
A modified variant of Fasciola hepatica FhSAP-2 (mFhSAP-2) as a recombinant vaccine candidate induces high-avidity IgG2c antibodies and enhances T cell activation in C57BL/6 mice
2025 · External reference
Evaluation of antibody response of sheep to foot-and-mouth disease vaccine prepared by using different MontanideTM oil adjuvants
10.47665/tb.38.1.027 · 2021 · External reference
The immunogenicity and tissue reactivity of Mycobacterium avium subsp paratuberculosis inactivated whole cell vaccine is dependent on the adjuvant used
10.1016/j.heliyon.2019.e01911 · 2019 · External reference
Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice
10.1016/j.imbio.2021.152057 · 2021 · External reference
Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle
10.1016/j.vaccine.2013.05.078 · 2013 · External reference
Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection
10.1016/j.vetpar.2010.04.042 · 2010 · External reference
Exposure to Fasciola hepatica miracidia increases the sensitivity of Lymnaea (Fossaria) humilis to high and low pH
10.1645/ge-3542rn.1 · 2006 · External reference
Vaccines for Fasciola: new thinking for an old problem
2021 · External reference
The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against Fasciola hepatica infection in sheep
10.1016/j.vaccine.2011.09.020 · 2011 · External reference
Comparative analysis of the viability of Fasciola hepatica eggs collected from fecal and gallbladder samples in experimentally infected sheep
10.1016/j.vetpar.2025.110631 · 2025 · External reference
Vaccination with cathepsin L phage-exposed mimotopes, single or in combination, reduce size, fluke burden, egg production and viability in sheep experimentally infected with Fasciola hepatica
10.1016/j.parint.2021.102355 · 2021 · External reference
Liver fluke vaccines in ruminants: strategies, progress and future opportunities
10.1016/j.ijpara.2014.07.011 · 2014 · External reference
The failure of a DNA prime/protein boost regime and CTLA-4 mediated targeting to improve the potency of a DNA vaccine encoding Fasciola hepatica phosphoglycerate kinase in sheep
10.1016/j.vetimm.2019.109941 · 2019 · External reference
Vaccination of sheep with Quil-A® adjuvant expands the antibody repertoire to the Fasciola MF6p/FhHDM-1 antigen and administered together impair the growth and antigen release of flukes
10.1016/j.vaccine.2018.02.115 · 2018 · External reference
Evaluation of a novel vaccine candidate derived from newly excysted juveniles of Fasciola hepatica in sheep
10.1038/s41598-025-00109-z · 2025 · External reference
Vaccination with cathepsin L mimotopes of Fasciola hepatica in goats reduces worm burden, morphometric measurements, and reproductive structures
10.1016/j.micpath.2021.104859 · 2021 · External reference
Pathological, immunological and parasitological study of sheep vaccinated with the recombinant protein 14-3-3z and experimentally infected with Fasciola hepatica
10.1016/j.vetimm.2018.07.006 · 2018 · External reference
Correlation of specific antibody titre and avidity with protection in cattle immunized against Fasciola hepatica
10.1016/s0264-410x(97)00289-2 · 1998 · External reference
Phage display-based vaccine with cathepsin L and excretory-secretory products mimotopes of Fasciola hepatica induces protective cellular and humoral immune responses in sheep
10.1016/j.vetpar.2020.109340 · 2021 · External reference
Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep
10.1186/s13567-021-00895-0 · 2021 · External reference
Safety and immunogenicity of an FhSAMS vaccine against Fasciola hepatica in dairy cattle
10.1111/pim.13074 · 2024 · External reference
Helminth vaccines in ruminants: from development to application
10.1016/j.cvfa.2019.10.001 · 2020 · External reference
